Jacob Hooker

Dr. Jacob Hooker is the Chief Executive Officer of Sensorium Therapeutics, a chemist, neuroscientist, and leading expert in molecular imaging whose work bridges modern neuroscience with ancient chemical intelligence. He brings a rare dual identity as both a scientific innovator and biotech entrepreneur. Dr. Hooker also serves as a part-time Lurie Family Professor of Radiology in the Field of Autism Research at Harvard Medical School; Massachusetts General Hospital, where he provides scientific leadership across neuroimaging and brain chemistry research programs.

Dr. Hooker received his PhD in Chemistry from the University of California, Berkeley, and subsequently completed both a Goldhaber Distinguished Fellowship and a Ruth Kirschstein Fellowship at Brookhaven National Laboratory, where he remained an Associate Scientist through 2013. In 2009, he joined the Athinoula A. Martinos Center for Biomedical Imaging at Massachusetts General Hospital, co-founding and co-directing a pioneering imaging facility that integrates functional MRI with positron emission tomography to advance neurochemical discovery in the human brain.

A recognized advisor in neurotherapeutics, Dr. Hooker has served on scientific advisory boards for organizations including Psy Therapeutics, Delix Therapeutics, and Fuzionaire Diagnostics and is a Science Advisor at Rocket Science Health (RSH). He co-founded Eikonizo Therapeutics in 2017 to apply molecular imaging in de-risking drug discovery for neurodegenerative diseases. In 2021, he co-founded Sensorium Therapeutics, where he now leads the development of breakthrough medicines inspired by nature’s chemical diversity and informed by cutting-edge neuroscience to address significant unmet needs in mental health and neurological disorders.